SAN DIEGO, May 31 /PRNewswire/ -- Immusol, Inc., a privately held biopharmaceutical company engaged in the discovery and development of novel therapies, announced today the appointments of Barry J. Simon, M.D. as Vice President of Clinical and Regulatory Affairs, with newly expanded responsibilities, and Zhu Shen, Ph.D. as Director of Business Development. Dr. Simon, who joined Immusol last August to lead company's efforts in the design and management of all clinical trial programs, will additionally assume oversight of Manufacturing and Quality. Dr. Shen will lead the Company's licensing and partnering efforts.
Dr. Simon brings to Immusol over twenty years of strong scientific and clinical experience in infectious diseases, anesthesiology, oncology, dermatology and virology, having served in numerous commercial and drug development roles at organizations, such as Roche Labs, Inc. and F. Hoffman La Roche, (Nutley, NJ), Connetics Corporation (Palo Alto, CA), and Immunomedics, Inc. (Morris Plains, NJ). Additionally he has served at the Albert Einstein College (New York, NY) of Medicine, The Mount Sinai Medical Center (NY, NY), and The New York Infirmary (NY, NY). Dr. Simon is a co-founder of two companies in biotechnology and had been an independent pharmaceutical consultant, advising clients regarding product licensing and commercialization initiatives. Dr. Simon received his M.D. from SUNY Downstate/Health Sciences Center in Brooklyn, N.Y., and was a Summa Cum Laude graduate of Hofstra University in Hempstead, N.Y.
Dr. Shen brings to Immusol considerable experience in marketing, strategic planning and business development. Prior to joining Immusol, Dr. Shen founded BioForesight, Inc., a life science strategic consulting company focusing on licensing, partnering, and financing for its clients in the US and Asia/China. Dr. Shen also held positions at The Wilkerson Group/ IBM, Bayer, and Chiron. She is an organizer, speaker, and chair of numerous international life science business conferences on licensing, venture capital investing, and Asia Pacific partnering. Dr. Shen received her Ph.D. in Biochemistry from the University of Colorado, and an MBA from Cornell University's Johnson School of Management. She attended Peking University and Peking Union Medical College in China.
"We are very honored that Barry and Zhu are bringing their years of pharmaceutical industry experience to reinforce Immusol's team," said Dr. Tsvi Goldenberg, Immusol's Chairman and CEO. "Barry's broad knowledge of pharmaceutical clinical development gives us the experience we will need as we move our products into the clinic. He additionally brings us experience in assessing medical strategies for in-licensing and out licensing initiatives which perfectly complements Zhu's experience. Zhu has developed extensive relationships and experience working with global pharmaceutical and biotech companies. She will be a great asset to us, as we focus on in-licensing clinical stage compounds and expanding our R&D collaborations. Zhu is a recognized thought leader in Asia Pacific life science business, which is an area that Immusol would like to explore further. Both Barry and Zhu's experience and leadership skills will be a positive influence on Immusol in executing our clinical development and licensing and partnering efforts."
Immusol is a privately-held San Diego-based biopharmaceutical company engaged in the discovery and development of novel therapies to treat human diseases. Immusol uses an integrated approach, starting with a proprietary discovery technology, to identify therapeutic molecules involved in the areas of cancer, viral infection, ophthalmology, and metabolic diseases. Based on these discoveries, Immusol develops small molecule and protein-based therapies alone or in collaboration with drug development partners. Immusol's lead drug candidate, ChelASE, is being studied in clinical trials for the treatment of keloids and hypertrophic scars. Other drug candidates are in various stages of pre-clinical and clinical development.